Local administration of IL-6 to stimulate Tfh cells in the lymph node could reverse the tumor-tolerant microenvironment in the D11 TDLN and recover its antitumor immunity (Fig. 5M), while direct effects of IL-6 on the primary tumor were ruled out (Fig. S9). The gene discussed is IL6; the disease is neoplasm.